uniQure (QURE) Financials: History & Chart

uniQure N.V.(QURE)

Biotechnology · Amsterdam, NH

$23.17+0.37 (+1.64%)

Delayed quote: Oct 6, 2026, 3:20 PM EDT

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Amsterdam, NH

221 employees

www.uniqure.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Matthew C. Kapusta

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	18.67M	5.84M	3.56M	5.57M	3.70M	5.26M	1.57M	5.22M	2.29M
Cost of Goods Sold	14.42M	10.39M	219K	3.40M	398K	656K	197K	619K	1.02M
Gross Profit	4.25M	-4.55M	3.34M	2.16M	3.30M	4.61M	1.37M	4.60M	1.27M
Gross Profit Margin	22.8%	-78.0%	93.9%	38.8%	89.2%	87.5%	87.4%	88.1%	55.4%
Total Operating Expenses	207.60M	51.33M	47.61M	54.32M	54.34M	48.47M	40.70M	50.43M	41.49M
Research & Development	131.34M	33.96M	29.18M	33.83M	34.37M	35.38M	36.14M	38.84M	30.59M
Selling, General & Administrative	75.51M	17.37M	20.07M	18.64M	19.44M	13.50M	10.91M	9.40M	11.69M
Operating Income (EBIT)	-203.35M	-55.88M	-44.27M	-52.16M	-51.03M	-43.87M	-39.33M	-45.83M	-40.23M
Operating Margin	-1089.1%	-956.8%	-1242.8%	-936.8%	-1379.0%	-833.6%	-2510.0%	-877.8%	-1759.0%
Income Before Tax (EBT)	-245.17M	-79.22M	-53.05M	-41.00M	-71.90M	-37.29M	-43.14M	-72.41M	-44.41M
Interest Income	19.60M	5.05M	5.23M	5.81M	3.50M	3.52M	4.13M	4.24M	4.87M
Interest Expense	59.69M	14.37M	14.03M	14.57M	16.72M	15.59M	15.11M	14.88M	16.61M
Other Income/Expense	-41.82M	-23.33M	-8.78M	11.16M	-20.87M	6.57M	-3.81M	-26.58M	-4.18M
Net Income	-252.21M	-81.06M	-53.53M	-37.09M	-80.53M	-37.72M	-43.64M	-73.26M	-44.38M
Income Tax Expense	7.04M	1.84M	488K	-3.92M	8.63M	425K	496K	856K	-31K
Net Profit Margin	-1350.7%	-1387.8%	-1502.9%	-666.1%	-2175.9%	-716.8%	-2784.7%	-1403.2%	-1940.4%
EBITDA	-188.88M	-50.98M	-41.31M	-49.19M	-47.40M	-40.23M	-34.80M	-41.47M	-37.24M
EBITDA Margin	-1011.6%	-872.8%	-1159.8%	-883.5%	-1280.8%	-764.6%	-2221.1%	-794.3%	-1628.4%
Depreciation & Amortization	14.46M	4.91M	2.96M	2.97M	3.63M	3.63M	4.53M	4.36M	2.99M
EPS Basic	-4.04	-1.22	-0.85	-0.59	-1.38	-0.69	-0.82	-1.50	-0.91
EPS Diluted	-4.04	-1.22	-0.85	-0.59	-1.38	-0.69	-0.82	-1.50	-0.91
Weighted Average Basic Shares	66.24M	66.24M	62.74M	57.50M	58.52M	54.81M	53.11M	48.84M	48.72M
Weighted Average Diluted Shares	66.24M	66.24M	62.74M	57.50M	58.52M	54.81M	53.11M	48.84M	48.72M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	16.10M	27.12M	15.84M	106.48M	524.00M	37.51M	7.28M	11.28M
Cost of Goods Sold	1.69M	18.33M	13.63M	3.34M	24.98M	122.40M	0.00	73.06M
Gross Profit	14.41M	8.79M	2.21M	103.14M	499.03M	-84.89M	7.28M	-61.78M
Gross Profit Margin	89.5%	32.4%	14.0%	96.9%	95.2%	-226.3%	100.0%	-547.5%
Total Operating Expenses	202.24M	193.09M	285.09M	246.30M	188.41M	40.54M	128.42M	99.52M
Research & Development	140.67M	143.78M	214.86M	197.59M	143.55M	122.40M	94.74M	74.81M
Selling, General & Administrative	65.34M	50.68M	73.08M	54.70M	56.29M	42.58M	33.54M	25.30M
Operating Income (EBIT)	-187.83M	-184.29M	-282.87M	-143.16M	310.62M	-125.43M	-121.14M	-88.23M
Operating Margin	-1166.8%	-679.6%	-1785.5%	-134.4%	59.3%	-334.3%	-1663.8%	-781.9%
Income Before Tax (EBT)	-193.34M	-237.13M	-306.56M	-128.26M	332.81M	-141.44M	-124.20M	-83.07M
Interest Income	16.97M	21.41M	19.56M	609K	162K	938K	3.55M	2.73M
Interest Expense	61.99M	63.74M	41.56M	11.70M	7.47M	3.83M	3.81M	2.16M
Other Income/Expense	-5.51M	-52.83M	-23.69M	14.90M	22.19M	-16.02M	-3.06M	5.16M
Net Income	-198.97M	-239.56M	-308.48M	-126.79M	329.59M	-125.02M	-124.20M	-83.30M
Income Tax Expense	5.63M	2.43M	1.92M	-1.47M	3.22M	-16.42M	0.00	231K
Net Profit Margin	-1236.0%	-883.4%	-1947.1%	-119.1%	62.9%	-333.3%	-1705.8%	-738.2%
EBITDA	-173.07M	-171.65M	-270.97M	-134.62M	317.92M	-114.78M	-114.47M	-81.33M
EBITDA Margin	-1075.1%	-633.0%	-1710.4%	-126.4%	60.7%	-306.0%	-1572.2%	-720.8%
Depreciation & Amortization	14.76M	12.64M	11.90M	8.54M	7.30M	10.65M	6.67M	6.90M
EPS Basic	-3.46	-4.92	-6.47	-2.71	7.17	-2.81	-3.20	-2.34
EPS Diluted	-3.46	-4.92	-6.47	-2.71	7.04	-2.81	-3.20	-2.34
Weighted Average Basic Shares	57.50M	48.65M	47.67M	46.74M	45.99M	44.47M	40.00M	35.64M
Weighted Average Diluted Shares	57.50M	48.65M	47.67M	46.74M	46.84M	44.47M	40.00M	35.64M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.